ESMO
Investigators are trialing methods to boost sensitivity for certain cancers, and assessing measures of how tests may impact clinical care in certain screening subpopulations.
Amgen's Lumakras Combo Scores High Response Rate in First-Line KRAS-Mutant Colorectal Cancer
Premium
Researchers reported at the ESMO Congress that 78 percent of patients responded to front-line treatment with Lumakras, Vectibix, and chemo.
Liquid Biopsy Elucidates Resistance Mechanisms With Targeted Treatment Combo in EGFR-Mutated NSCLC
Premium
Analysis of ctDNA in the MARIPOSA trial showed fewer EGFR alterations and MET amplifications after Rybrevant-Lazcluze treatment than after Tagrisso.
Researchers analyzed molecular and particulate matter exposure data on nearly 9,000 NSCLC patients in France and confirmed a link reported by UK scientists in 2022.
Researchers at the ESMO Congress presented data showing better responses on dual-checkpoint blockade in the biomarker-defined subset relative to all-comers.